Research study Program year 2025 Source: CMS Open Payments

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living With Overweight or Obesity

Research payments

$172,877

12 payments

Through program year 2025, $172,877 in research payments was reported against A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living With Overweight or Obesity, across 12 payments, paid by Amgen Inc..

Paid by: Amgen Inc.
ClinicalTrials.gov: No trial number was reported for this study

By program year

1 row

Year	Kind	Amount	Payments
2025	Research	$172,877	12

Breakdown

Who paid Research payments · program year 2025

Amgen Inc. $172,877 12 payments

Who received the money Research payments · program year 2025

Epic Medical Research LLC Organisation paid for research $34,000 1 payment
Monroe Biomedical Research LLC Organisation paid for research $20,348 1 payment
Peninsula Research Associates Organisation paid for research $19,994 1 payment
Northwest Clinical Research Center, Inc., P.C. Organisation paid for research $19,500 1 payment
Basil Clinical Organisation paid for research $15,447 1 payment
Futuresearch Trials Of Neurology Organisation paid for research $13,137 1 payment
Epic Medical Research - Desoto Organisation paid for research $12,270 1 payment
CTI Clinical Research Center Organisation paid for research $12,270 1 payment
Clinical Research Center Of Florida Organisation paid for research $12,270 1 payment
Northwest Clinical Research Center Organisation paid for research $4,547 1 payment

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

10 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.

Cite this record

“A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living With Overweight or Obesity”, Who Paid My Doc, citing CMS Open Payments, program year 2025. https://www.whopaidmydoc.com/research-studies/a-phase-3-randomized-double-blind-placebo-controlled-study-to-evaluate-the-efficacy-safety-and-tolerability-of-maridebart-cafraglutide-in-adult-participants-with-obstructive-sleep-apnea-on-positive-airway-pressure-therapy-and-living-with-overweight-or-obesity-60964963

Figures here may be reproduced with attribution and a link — see for journalists and researchers.